Keeping Oral ESRD Drugs Out Of Bundled Payment Could Save Medicare Up To $4 Bil. By 2026 – CBO
This article was originally published in The Pink Sheet Daily
Executive Summary
The Congressional Budget Office projects it will be less expensive for Medicare Part D to continue covering oral drugs used in treating end-stage renal disease because market forces will drive down costs once generic competition arrives in 2014, rather than include them in the Part B bundled payment for ESRD treatment.